AstraZeneca’s AZD0120 Multiple Myeloma Trial Highlights Intensifying BCMA Competition

According to a recent LinkedIn post from BioSpectator Inc, AstraZeneca is progressing its BCMAxCD19 CAR-T candidate AZD0120 directly into a Phase 3 trial in second-line multiple myeloma, comparing it head-to-head with standard-of-care therapy. The post notes that AZD0120 originated from AstraZeneca’s acquisition of China-based Gracell Biotechnologies roughly two years ago, framing this as an aggressive differentiation strategy versus competitors.

The LinkedIn commentary suggests AstraZeneca is looking to leverage recent U.S. FDA regulatory shifts around accelerated approvals in multiple myeloma to advance its cell therapy pipeline more quickly. At the same time, it highlights that Johnson & Johnson is raising the competitive bar in the indication, underscoring a highly dynamic and potentially volatile landscape for late-line and second-line myeloma treatments.

According to the post, a major competitive variable is the emergence of bispecific antibody combination regimens. It cites data presented by J&J at the American Society of Hematology (ASH) suggesting its BCMAxCD3 bispecific teclistamab (Tekvayli) combined with the CD38 antibody daratumumab (Darzalex) delivered unprecedented efficacy versus standard of care, which could reshape treatment standards and payer expectations.

The post further notes that such bispecific combinations may even threaten J&J’s own BCMA CAR-T product Carvykti, which reached blockbuster status with $1.7 billion in sales last year. For investors, the described developments point to intensifying competition, rapid innovation cycles, and growing regulatory and clinical risk for companies pursuing BCMA-targeted cell and bispecific therapies, potentially influencing valuation dispersion across the multiple myeloma treatment space.